136 related articles for article (PubMed ID: 31375290)
1. Essential structure of orexin 1 receptor antagonist YNT-707, Part IV: The role of D-ring in 4,5-epoxymorphinan on the orexin 1 receptor antagonistic activity.
Saitoh T; Seki K; Nakajima R; Yamamoto N; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2019 Sep; 29(18):2655-2658. PubMed ID: 31375290
[TBL] [Abstract][Full Text] [Related]
2. Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor.
Yamamoto N; Ohrui S; Okada T; Yata M; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2017 Sep; 27(17):4176-4179. PubMed ID: 28739044
[TBL] [Abstract][Full Text] [Related]
3. Essential structure of orexin 1 receptor antagonist YNT-707, part V: Structure-activity relationship study of the substituents on the 17-amino group.
Saitoh T; Seki K; Nakajima R; Yamamoto N; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2020 Feb; 30(3):126893. PubMed ID: 31879208
[TBL] [Abstract][Full Text] [Related]
4. Essential structure of orexin 1 receptor antagonist YNT-707, part III: Role of the 14-hydroxy and the 3-methoxy groups in antagonistic activity toward the orexin 1 receptor in YNT-707 derivatives lacking the 4,5-epoxy ring.
Yamamoto N; Ohrui S; Okada T; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
Bioorg Med Chem; 2019 Apr; 27(8):1747-1758. PubMed ID: 30871861
[TBL] [Abstract][Full Text] [Related]
5. Essential structure of orexin 1 receptor antagonist YNT-707: Conversion of the 16-cyclopropylmethyl group to the 16-sulfonamide group in d-nor-nalfurafine derivatives.
Katoh K; Kutsumura N; Yamamoto N; Nagumo Y; Saitoh T; Ishikawa Y; Irukayama-Tomobe Y; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2022 Mar; 59():128550. PubMed ID: 35041942
[TBL] [Abstract][Full Text] [Related]
6. Essential structure of orexin 1 receptor antagonist YNT-707, Part II: Drastic effect of the 14-hydroxy group on the orexin 1 receptor antagonistic activity.
Ohrui S; Yamamoto N; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2018 Feb; 28(4):774-777. PubMed ID: 29338909
[TBL] [Abstract][Full Text] [Related]
7. Effect of removal of the 14-hydroxy group on the affinity of the 4,5-epoxymorphinan derivatives for orexin and opioid receptors.
Katoh K; Yamamoto N; Ishikawa Y; Irukayama-Tomobe Y; Tanimura R; Saitoh T; Nagumo Y; Kutsumura N; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2022 Mar; 59():128527. PubMed ID: 35007722
[TBL] [Abstract][Full Text] [Related]
8. Discovery of attenuation effect of orexin 1 receptor to aversion of nalfurafine: Synthesis and evaluation of D-nor-nalfurafine derivatives and analyses of the three active conformations of nalfurafine.
Nagumo Y; Katoh K; Iio K; Saitoh T; Kutsumura N; Yamamoto N; Ishikawa Y; Irukayama-Tomobe Y; Ogawa Y; Baba T; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2020 Sep; 30(17):127360. PubMed ID: 32738987
[TBL] [Abstract][Full Text] [Related]
9. Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies.
Nagase H; Yamamoto N; Yata M; Ohrui S; Okada T; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ishikawa Y; Ogawa Y; Hirayama S; Kuroda D; Watanabe Y; Gouda H; Yanagisawa M
J Med Chem; 2017 Feb; 60(3):1018-1040. PubMed ID: 28051300
[TBL] [Abstract][Full Text] [Related]
10. Structure-based development of a subtype-selective orexin 1 receptor antagonist.
Hellmann J; Drabek M; Yin J; Gunera J; Pröll T; Kraus F; Langmead CJ; Hübner H; Weikert D; Kolb P; Rosenbaum DM; Gmeiner P
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18059-18067. PubMed ID: 32669442
[TBL] [Abstract][Full Text] [Related]
11. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
Stump CA; Cooke AJ; Bruno J; Cabalu TD; Gotter AL; Harell CM; Kuduk SD; McDonald TP; O'Brien J; Renger JJ; Williams PD; Winrow CJ; Coleman PJ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5809-5814. PubMed ID: 27818110
[TBL] [Abstract][Full Text] [Related]
12. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.
Sifferlen T; Boller A; Chardonneau A; Cottreel E; Gatfield J; Treiber A; Roch C; Jenck F; Aissaoui H; Williams JT; Brotschi C; Heidmann B; Siegrist R; Boss C
Bioorg Med Chem Lett; 2015 May; 25(9):1884-91. PubMed ID: 25838147
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach.
Heidmann B; Gatfield J; Roch C; Treiber A; Tortoioli S; Brotschi C; Williams JT; Bolli MH; Abele S; Sifferlen T; Jenck F; Boss C
ChemMedChem; 2016 Oct; 11(19):2132-2146. PubMed ID: 27390287
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.
Zhang D; Perrey DA; Decker AM; Langston TL; Mavanji V; Harris DL; Kotz CM; Zhang Y
J Med Chem; 2021 Jun; 64(12):8806-8825. PubMed ID: 34101446
[TBL] [Abstract][Full Text] [Related]
15. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia.
Futamura A; Suzuki R; Tamura Y; Kawamoto H; Ohmichi M; Hino N; Tokumaru Y; Kirinuki S; Hiyoshi T; Aoki T; Kambe D; Nozawa D
Bioorg Med Chem; 2020 Jul; 28(13):115489. PubMed ID: 32482533
[TBL] [Abstract][Full Text] [Related]
16. Discovery of orexin 2 receptor selective and dual orexin receptor agonists based on the tetralin structure: Switching of receptor selectivity by chirality on the tetralin ring.
Iio K; Saitoh T; Ohshita R; Hino T; Amezawa M; Takayama Y; Nagumo Y; Yamamoto N; Kutsumura N; Irukayama-Tomobe Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2022 Mar; 60():128555. PubMed ID: 35051577
[TBL] [Abstract][Full Text] [Related]
17. Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.
Perrey DA; German NA; Decker AM; Thorn D; Li JX; Gilmour BP; Thomas BF; Harris DL; Runyon SP; Zhang Y
ACS Chem Neurosci; 2015 Apr; 6(4):599-614. PubMed ID: 25643283
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of novel orexin 2 receptor agonists based on naphthalene skeleton.
Hino T; Saitoh T; Nagumo Y; Yamamoto N; Kutsumura N; Irukayama-Tomobe Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2022 Mar; 59():128530. PubMed ID: 35007725
[TBL] [Abstract][Full Text] [Related]
19. Syntheses of 4,6'-epoxymorphinan derivatives and their pharmacologies.
Nemoto T; Fujii H; Narita M; Miyoshi K; Nakamura A; Suzuki T; Nagase H
Bioorg Med Chem; 2008 Apr; 16(8):4304-12. PubMed ID: 18337104
[TBL] [Abstract][Full Text] [Related]
20. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C
ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
